Hints and tips:
Related Special Reports
...Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, plans to invest up to $7bn annually by 2030, as dividend payments from the maker of diabetes drug Ozempic and weight loss treatment...
...Swiss company Roche acquired obesity drug developer Carmot Therapeutics for $3.1bn last month, while AstraZeneca signed a $2bn licensing agreement with Eccogene, a Chinese maker of an oral obesity drug in...
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...The company’s last major acquisition was the $16.6bn takeover of heart device maker Abiomed in November 2022....
...China is one of the world’s largest makers of active pharmaceutical ingredients and antibiotics and a major supplier of drugs to the EU and US....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
..., and would cap what Barclays analysts have described as an “unexpectedly strong start to the year” for the company, which has been the best-performing large pharma stock in Europe behind Novo Nordisk, maker...
...Novo Nordisk, the maker of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, said the deal was an “important step” in its strategy to “establish a presence in cardiovascular disease”....
...A top-five shareholder in struggling Covid-19 vaccine maker Novavax is calling for an “urgent shake-up” of the board and an overhaul of its sales strategy, as the stock is down 99 per cent from its pandemic...
...The UK Medicines and Healthcare Regulatory Agency (MHRA) has also struggled to approve drugs at the same rate as the EU, making it difficult for makers of generic medicines to enter the UK market....
...The acquisition of Cardior Pharmaceuticals will give Novo Nordisk a treatment for heart failure in mid-stage trials that targets the root causes of heart disease....
...The US market is the engine of the global pharmaceutical industry. Its exceptionally high drug prices help deliver as much as three-quarters of the sector’s global profits....
...Those from Chinese groups Shanghai Benemae Pharmaceutical and Huadong Medicine have recently received approval....
...of US seed maker Monsanto, which was masterminded by Baumann and executed despite staunch shareholder opposition....
...For that reason, the 2023 FT Person of the Year went to Lars Fruergaard Jørgensen, chief executive of Novo Nordisk, the pharmaceutical company that brought these successful weight-loss drugs to market....
...pharmaceutical care....
...Grifols: Shares in the Spanish pharmaceutical company fell 3.6 per cent after short seller Gotham City Research issued a second report on the relationship between the medicine maker and related family vehicle...
...from the fallout of its ill-fated $63bn takeover of US seeds-maker Monsanto in 2016, which saddled the company with billions in debt and exposed it to costly litigation over Roundup....
...That ambition, the Association of the British Pharmaceutical Industry says, is contingent on “[making] sure we do not forget the lessons we learned during the pandemic”....
...During the pandemic, customers also included decision makers outside the pharmaceutical industry....
...The maker of Panadol painkillers, which was spun off from GSK and Pfizer in 2022, said it expected organic revenue growth of 4-6 per cent in 2024, ahead of analyst estimates of 4.5 per cent....
...Electric-car maker Tesla registered expenses of about $2.4mn for its chief executive Elon Musk in 2023, with a further $500,000 spent in the first two months of this year....
...Eli Lilly’s $1.4bn acquisition of Point Biopharma Global is good news for the battered sector. Cheaper valuations have finally drawn cash-rich pharmaceutical makers back to biotechs....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Eli Lilly: The maker of weight loss drug Mounjaro is expected to report this morning that revenue increased more than 22 per cent year-on-year to $8.9bn in the three months that ended in December....
International Edition